User profiles for Joshua J. Skydel
 | Joshua J. SkydelDartmouth Hitchcock Medical Center Verified email at hitchcock.org Cited by 146 |
Reporting of study participant demographic characteristics and demographic representation in Premarketing and postmarketing studies of novel cancer therapeutics
Importance Adequate representation of demographic subgroups in premarketing and
postmarketing clinical studies is necessary for understanding the safety and efficacy associated …
postmarketing clinical studies is necessary for understanding the safety and efficacy associated …
Feasibility of using real-world data to emulate postapproval confirmatory clinical trials of therapeutic agents granted US Food and Drug Administration accelerated …
Under the accelerated approval pathway of the US Food and Drug Administration (FDA),
therapeutic agents targeting serious or life-threatening diseases can receive approval on the …
therapeutic agents targeting serious or life-threatening diseases can receive approval on the …
Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for …
Objective To systematically identify, match, and compare treatment effects and study
demographics from individual or meta-analysed observational studies and randomized controlled …
demographics from individual or meta-analysed observational studies and randomized controlled …
Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year
Objective To estimate the financial costs paid by individual medical researchers from meeting
the article processing charges (APCs) levied by open access journals in 2019. Design …
the article processing charges (APCs) levied by open access journals in 2019. Design …
Characteristics and reporting of number needed to treat, number needed to harm, and absolute risk reduction in controlled clinical trials, 2001-2019
Methods| We identified the 6 most-cited medical journals according to InCites Journal
Citation Reports (Clarivate Analytics 2019)(Table 1). For each journal, we reviewed all issues …
Citation Reports (Clarivate Analytics 2019)(Table 1). For each journal, we reviewed all issues …
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018
Background/Aims The US Food and Drug Administration outlines clinical studies as
postmarketing requirements and commitments to be fulfilled following approval of new drugs and …
postmarketing requirements and commitments to be fulfilled following approval of new drugs and …
[HTML][HTML] Spending by the Centers for Medicare & Medicaid Services before and after confirmation of benefit for drugs granted US Food and Drug Administration …
Importance Accelerated approval by the US Food and Drug Administration (FDA) grants
market authorization for drugs based on clinical trials using surrogate end points likely to …
market authorization for drugs based on clinical trials using surrogate end points likely to …
Analysis of postapproval clinical trials of therapeutics approved by the US Food and Drug Administration without clinical postmarketing requirements or commitments
JJ Skydel, AT Luxkaranayagam, SS Dhruva… - JAMA network …, 2019 - jamanetwork.com
Importance The US Food and Drug Administration (FDA) can use postmarketing requirements
to mandate pharmaceutical companies to conduct clinical trials after the approval of novel …
to mandate pharmaceutical companies to conduct clinical trials after the approval of novel …
[HTML][HTML] Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the …
Objectives To evaluate National Comprehensive Cancer Network (NCCN) guideline
recommendations for oncology drug treatments that have been granted accelerated approval, and …
recommendations for oncology drug treatments that have been granted accelerated approval, and …
Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies
JJ Skydel, R Ramachandran, S Suttiratana… - The Journal of …, 2024 - jrheum.org
Clinical research into potential therapies for systemic lupus erythematosus (SLE) has
increased over the last 2 decades, driven by the discovery of new targetable pathways, yet …
increased over the last 2 decades, driven by the discovery of new targetable pathways, yet …